Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?
- PMID: 36149616
- DOI: 10.1007/s10792-022-02540-x
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?
Abstract
Purpose: To investigate the relationship between the development of corrected 1-year-old refraction values and risk factors in preterm infants who underwent laser photocoagulation (LPC) therapy for retinopathy of prematurity (ROP).
Methods: The ophthalmic examination findings of preterm neonates who had developed Type I ROP and received LPC therapy were evaluated retrospectively. The association between spherical equivalent (SE) values and clinical findings were analyzed by using multivariable linear regression analysis.
Results: The study included 157 eyes of 80 neonates with a mean birth week of 27.1 ± 2.2 weeks (23 to 32 weeks) and a mean birth weight of 995 ± 273 g (565 to 1760 g). The treatments were administered on an average of 36.8 ± 2.7 (32 to 45 weeks) postmenstrual age. LPC treatment was applied bilaterally to 77 of the 80 neonates included in the study, and unilaterally to 3 of them. The mean ± standard deviation of the SE value was 0.31 ± 1.89 diopters (D) (- 8.00 to 4.63 D) according to the results of the 1-year corrected age refraction examination. In univariate analysis, no significant association between GA, BW, and ROP zone and SE value, while the number of laser spots (ß = - 0.27 ± 0.00 D, p = 0.00) and stage 3 ROP (ß = - 0.29 ± 0.37 D, p = 0.00) were significantly associated with the SE value. In multivariable linear regression analysis, a significant association between number of laser spot, stage 3 ROP and SE value (ß = - 0.25 ± 0.00 D, p = 0.01 for number of laser spot, ß = - 0.28 ± 0.36 D, p = 0.00 for stage 3 ROP).
Conclusion: In conclusion, this study supports that stage of ROP and the number of laser spots count applied in photocoagulation treatment for ROP is significantly correlated with degree of myopia (p < 0.05).
Keywords: Laser treatment; Myopia; Refractive outcome; Retinopathy of prematurity.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.Eye (Lond). 2021 Oct;35(10):2820-2825. doi: 10.1038/s41433-020-01321-z. Epub 2020 Nov 30. Eye (Lond). 2021. PMID: 33257802 Free PMC article.
-
One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.Int Ophthalmol. 2023 Jul;43(7):2197-2202. doi: 10.1007/s10792-022-02615-9. Epub 2022 Dec 15. Int Ophthalmol. 2023. PMID: 36522564
-
Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Curr Eye Res. 2017 Mar;42(3):462-469. doi: 10.1080/02713683.2016.1196709. Epub 2016 Jul 15. Curr Eye Res. 2017. PMID: 27420302
-
Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study.Graefes Arch Clin Exp Ophthalmol. 2022 Dec;260(12):3809-3816. doi: 10.1007/s00417-022-05730-6. Epub 2022 Jun 22. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35729410
-
Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.PLoS One. 2019 Dec 2;14(12):e0225643. doi: 10.1371/journal.pone.0225643. eCollection 2019. PLoS One. 2019. PMID: 31790445 Free PMC article.
Cited by
-
Refractive error in preterm infants without retinopathy of prematurity aged 1-18 months: A propensity score matching analysis.J Optom. 2025 Jul-Sep;18(3):100559. doi: 10.1016/j.optom.2025.100559. Epub 2025 May 17. J Optom. 2025. PMID: 40382889 Free PMC article.
-
A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity.J Clin Med. 2025 Jan 26;14(3):810. doi: 10.3390/jcm14030810. J Clin Med. 2025. PMID: 39941480 Free PMC article. Review.
References
-
- Hartnett ME (2017) Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol 62:257–276. https://doi.org/10.1016/j.survophthal.2016.12.004 - DOI - PubMed
-
- Gaber R, Sorour OA, Sharaf AF, Saad HA (2021) Incidence and risk factors for retinopathy of prematurity (ROP) in biggest neonatal intensive care unit in Itay Elbaroud City, Behera Province. Egypt Clin Ophthalmol 15:3467–3471. https://doi.org/10.2147/OPTH.S324614 - DOI - PubMed
-
- Al-Qahtani B, Al-Otaibi M, Alabdulajabbar K, Selayem NB, Alshehri W, Omair A et al (2019) Retinopathy of prematurity incidence and risk factors in a tertiary hospital in Riyadh, Saudi Arabia. Middle East Afr J Ophthalmol 26:235–239. https://doi.org/10.4103/meajo.MEAJO_131_18 - DOI - PubMed
-
- Dhingra D, Katoch D, Dutta S, Samanta R, Aggarwal K, Dogra MR (2019) Change in the incidence and severity of retinopathy of prematurity (ROP) in a neonatal intensive care unit in Northern India after 20 years: comparison of two similar prospective cohort studies. Ophthalmic Epidemiol 26:169–174. https://doi.org/10.1080/09286586.2018.1562082 - DOI - PubMed
-
- Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S et al (2015) Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA 314:1039–1051. https://doi.org/10.1001/jama.2015.10244 - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources